ATE306546T1 - Rekombinanter vaskulärer endothelzellen wachstumsfaktor d (vegf-d) - Google Patents

Rekombinanter vaskulärer endothelzellen wachstumsfaktor d (vegf-d)

Info

Publication number
ATE306546T1
ATE306546T1 AT97938486T AT97938486T ATE306546T1 AT E306546 T1 ATE306546 T1 AT E306546T1 AT 97938486 T AT97938486 T AT 97938486T AT 97938486 T AT97938486 T AT 97938486T AT E306546 T1 ATE306546 T1 AT E306546T1
Authority
AT
Austria
Prior art keywords
vegf
endothelial cell
growth factor
cell growth
vascular endothelial
Prior art date
Application number
AT97938486T
Other languages
English (en)
Inventor
Marc G Achen
Andrew F Wilks
Steven A Stacker
Kari Alitalo
Original Assignee
Ludwig Inst Cancer Res
Univ Helsinki Licensing
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46149776&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE306546(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from AUPO1825A external-priority patent/AUPO182596A0/en
Priority claimed from AUPO3554A external-priority patent/AUPO355496A0/en
Priority claimed from AUPO4954A external-priority patent/AUPO495497A0/en
Priority claimed from AUPO7435A external-priority patent/AUPO743597A0/en
Application filed by Ludwig Inst Cancer Res, Univ Helsinki Licensing filed Critical Ludwig Inst Cancer Res
Application granted granted Critical
Publication of ATE306546T1 publication Critical patent/ATE306546T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT97938486T 1996-08-23 1997-08-21 Rekombinanter vaskulärer endothelzellen wachstumsfaktor d (vegf-d) ATE306546T1 (de)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US2375196P 1996-08-23 1996-08-23
AUPO1825A AUPO182596A0 (en) 1996-08-23 1996-08-23 Growth factor
AUPO3554A AUPO355496A0 (en) 1996-11-11 1996-11-11 Growth factor
US3109796P 1996-11-14 1996-11-14
AUPO4954A AUPO495497A0 (en) 1997-02-05 1997-02-05 Growth factors
US3881497P 1997-02-10 1997-02-10
AUPO7435A AUPO743597A0 (en) 1997-06-19 1997-06-19 Growth factor
US5142697P 1997-07-01 1997-07-01
PCT/US1997/014696 WO1998007832A1 (en) 1996-08-23 1997-08-21 Recombinant vascular endothelial cell growth factor d (vegf-d)

Publications (1)

Publication Number Publication Date
ATE306546T1 true ATE306546T1 (de) 2005-10-15

Family

ID=46149776

Family Applications (2)

Application Number Title Priority Date Filing Date
AT97938486T ATE306546T1 (de) 1996-08-23 1997-08-21 Rekombinanter vaskulärer endothelzellen wachstumsfaktor d (vegf-d)
AT06121918T ATE434034T1 (de) 1996-08-23 1997-08-21 Rekombinanter vasculärer endothelzellen wachstumsfaktor d (vegf-d)

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT06121918T ATE434034T1 (de) 1996-08-23 1997-08-21 Rekombinanter vasculärer endothelzellen wachstumsfaktor d (vegf-d)

Country Status (11)

Country Link
US (14) US6235713B1 (de)
EP (4) EP0956339B1 (de)
JP (3) JP2001517075A (de)
AT (2) ATE306546T1 (de)
AU (1) AU729880C (de)
CA (1) CA2263890C (de)
DE (2) DE69734359T2 (de)
DK (3) DK0956339T3 (de)
ES (3) ES2390107T3 (de)
HK (1) HK1025789A1 (de)
WO (1) WO1998007832A1 (de)

Families Citing this family (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6824777B1 (en) 1992-10-09 2004-11-30 Licentia Ltd. Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy
AU696764B2 (en) 1994-03-08 1998-09-17 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US6040157A (en) 1994-03-08 2000-03-21 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US7153827B1 (en) 1994-03-08 2006-12-26 Human Genome Sciences, Inc. Vascular endothelial growth factor 2 and methods of use
US6608182B1 (en) 1994-03-08 2003-08-19 Human Genome Sciences, Inc. Human vascular endothelial growth factor 2
US5932540A (en) 1994-03-08 1999-08-03 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US6734285B2 (en) 1994-03-08 2004-05-11 Human Genome Sciences, Inc. Vascular endothelial growth factor 2 proteins and compositions
US7109308B1 (en) 1994-03-08 2006-09-19 Human Genome Sciences, Inc. Antibodies to human vascular endothelial growth factor 2
US7186688B1 (en) 1994-03-08 2007-03-06 Human Genome Sciences, Inc. Methods of stimulating angiogenesis in a patient by administering vascular endothelial growth factor 2
US7423125B2 (en) 1995-08-01 2008-09-09 Vegenics Limited Antibodies to VEGF-C
EP0848755B2 (de) 1995-09-08 2011-02-09 Genentech, Inc. Vegf-verwandtes protein
AU7142996A (en) 1995-09-29 1997-04-28 Universita' Degli Studi Di Siena Regulated genes and uses thereof
US7357927B2 (en) 1996-03-12 2008-04-15 Human Genome Sciences, Inc. Death domain containing receptors
WO1997033904A1 (en) 1996-03-12 1997-09-18 Human Genome Sciences, Inc. Death domain containing receptors
US6713061B1 (en) 1996-03-12 2004-03-30 Human Genome Sciences, Inc. Death domain containing receptors
US6635743B1 (en) 1996-03-22 2003-10-21 Human Genome Sciences, Inc. Apoptosis inducing molecule II and methods of use
US7964190B2 (en) 1996-03-22 2011-06-21 Human Genome Sciences, Inc. Methods and compositions for decreasing T-cell activity
EP0935001B2 (de) * 1996-07-15 2011-08-10 Chugai Seiyaku Kabushiki Kaisha Neuartige vegf-ähnliche faktoren
EP0956339B1 (de) 1996-08-23 2005-10-12 Ludwig Institute For Cancer Research Rekombinanter vaskulärer endothelzellen wachstumsfaktor d (vegf-d)
US7125714B2 (en) 1997-02-05 2006-10-24 Licentia Ltd. Progenitor cell materials and methods
US20020137890A1 (en) * 1997-03-31 2002-09-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6391311B1 (en) 1998-03-17 2002-05-21 Genentech, Inc. Polypeptides having homology to vascular endothelial cell growth factor and bone morphogenetic protein 1
AU765888B2 (en) * 1997-12-24 2003-10-02 Vegenics Limited Expression vectors and cell lines expressing vascular endothelial growth factor D, and method of treating melanomas
EP1054687B8 (de) * 1997-12-24 2008-07-16 Vegenics Limited Expressionsvektoren und zellinien zur expression von vaskulärem wachstumsfaktor d, sowie verfahren zur behandlung von melanomen
DK2016951T3 (da) * 1998-03-17 2012-09-24 Genentech Inc VEGF- og BMP1-homologe polypeptider
EP0984063A3 (de) * 1998-08-31 2000-08-16 Eli Lilly And Company Vegf-verwandtes gen und protein
US20030082670A1 (en) * 1998-09-30 2003-05-01 Ulf Eriksson Platelet-derived growth factor C, DNA coding therefor, and uses thereof
US20040053837A1 (en) * 1998-09-30 2004-03-18 Ludwig Institute For Cancer Research Composition and method for modulating vasculogenesis or angiogenesis
US20030211994A1 (en) * 1998-09-30 2003-11-13 Ludwig Institute For Cancer Research Composition and method for modulating vasculogenesis or angiogenesis
DE69942981D1 (de) 1998-10-09 2011-01-05 Vegenics Ltd Flt4 (vegfr-3) als ziel für tumornachweis (imaging) und antitumortherapie
US6958147B1 (en) 1998-10-26 2005-10-25 Licentia Ltd Use of VEGF-C to prevent restenosis
ATE275417T1 (de) * 1998-10-26 2004-09-15 Ludwig Inst Cancer Res Verwendung von vegf-c und vegf-d genen oder proteinen zur vorbeugung der restenose
EP1568375A1 (de) * 1998-10-26 2005-08-31 Ludwig Institute For Cancer Research Verwendung von VEGF-C oder VEGF-D Genen oder Proteinen zur Vorbeugung der Restenose
JP2002534061A (ja) 1998-11-10 2002-10-15 ルードヴィッヒ・インスティテュート・フォア・キャンサー・リサーチ 血小板由来増殖因子ｄ、それをコードするｄｎａ、及びその利用法
EP1137773B1 (de) * 1998-12-07 2008-08-13 ZymoGenetics, Inc. Wachstumsfaktor-homologe zvegf-3
DK1140175T3 (da) * 1998-12-21 2006-08-14 Ludwig Inst Cancer Res Antistoffer mod trunkeret VEGF-D og anvendelser deraf
US6783953B1 (en) 1998-12-22 2004-08-31 Janssen Pharmaceutica N.V. Vascular endothelial growth factor-X
DK1141293T3 (da) * 1998-12-22 2007-11-12 Janssen Pharmaceutica Nv Vaskulær endotelial vækstfaktor-X
US7223724B1 (en) 1999-02-08 2007-05-29 Human Genome Sciences, Inc. Use of vascular endothelial growth factor to treat photoreceptor cells
AU3501700A (en) 1999-02-26 2000-09-14 Human Genome Sciences, Inc. Human endokine alpha and methods of use
US6764820B2 (en) 1999-03-26 2004-07-20 Ludwig Institute For Cancer Research Screening for lymphatic disorders involving the FLT4 receptor tyrosine kinase (VEGFR-3)
NZ514434A (en) * 1999-03-26 2003-11-28 Univ California Modulation of vascular permeability by means of TIE2 receptor activators
WO2000058511A1 (en) 1999-03-26 2000-10-05 Ludwig Institute For Cancer Research Screening and therapy for lymphatic disorders involving the flt4 receptor tyrosine kinase (vegfr-3)
US6372494B1 (en) 1999-05-14 2002-04-16 Advanced Tissue Sciences, Inc. Methods of making conditioned cell culture medium compositions
CA2381985A1 (en) * 1999-08-16 2001-02-22 Universita'degli Studi Di Siena Vegf-d and angiogenic use thereof
US6921763B2 (en) 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
US7045133B2 (en) 2000-01-18 2006-05-16 Ludwig Institute For Cancer Research VEGF-D/VEGF-C/VEGF peptidomimetic inhibitor
US7727971B2 (en) 2000-02-04 2010-06-01 Life Sciences Research Partners Vzw Use of placental growth factor for treating ischemic muscle disease
US6930089B2 (en) 2000-02-04 2005-08-16 D. Collen Research Foundation Vzw Use of vascular endothelial growth factor, placenta growth factor or both for preventing or treating ischemic disease or stroke
US7105168B1 (en) 2002-06-04 2006-09-12 D. Collen Research Foundation Vzw Method of improving ischemic muscle function by administering placental growth factor
AU4643501A (en) * 2000-02-04 2001-08-14 Flanders Interuniversity Institute For Biotechnology (Vib) Use of vascular endothelial growth factor, placenta growth factor or both for preventing or treating ischemic diseases or stroke
PL357099A1 (en) 2000-02-07 2004-07-12 Abbott Gmbh & Co.Kg 2-benzothiazolyl urea derivatives and their use as protein kinase inhibitors
JP4981229B2 (ja) 2000-02-25 2012-07-18 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ ハイブリッド血管内皮成長因子ＤＮＡｓおよびタンパク質に関与する物質および方法
ES2234818T3 (es) * 2000-03-02 2005-07-01 Ludwig Institute For Cancer Research Procedimiento para tratar canceres que expresan el factor de crecimiento endotelial d.
AU2006201128B2 (en) * 2000-03-02 2009-05-28 Vegenics Limited Methods for treating, screening for, and detecting cancers expressing vascular endothelial growth factor D
US20020102260A1 (en) * 2000-03-02 2002-08-01 Marc Achen Methods for treating neoplastic disease characterized by vascular endothelial growth factor D expression, for screening for neoplastic disease or metastatic risk, and for maintaining vascularization of tissue
EP1519193B1 (de) * 2000-03-02 2011-11-09 Vegenics Pty Ltd Verfahren zum Auffinden von Tumoren welche den vaskulären endothelialen Wachstumsfaktor D exprimieren
EP1278544A4 (de) 2000-04-12 2004-08-18 Human Genome Sciences Inc Albumin fusionsproteine
AU6456501A (en) * 2000-05-03 2001-11-12 Ludwig Inst Cancer Res A method for activating only the vascular endothelial growth factor receptor-3 and uses thereof
EP1313512A4 (de) 2000-08-04 2004-08-25 Human Genome Sciences Inc Vaskulärer endothel-wachstumsfaktor 2(15.02.02)
US6793918B2 (en) * 2000-11-01 2004-09-21 Ludwig Institute For Cancer Research In vivo stimulation of angiogenic activity
US7067317B2 (en) 2000-12-07 2006-06-27 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
US7026462B2 (en) 2000-12-07 2006-04-11 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
US7611711B2 (en) 2001-01-17 2009-11-03 Vegenics Limited VEGFR-3 inhibitor materials and methods
CN1494552A (zh) 2001-01-19 2004-05-05 ·��ά��֢�о�Ժ Flt4(VEGFR-3)作为靶用于肿瘤成像和抗肿瘤治疗
US20020164624A1 (en) * 2001-02-12 2002-11-07 Waldemar Debinski VEGF-D expression in brain cancer
MXPA03008560A (es) 2001-03-22 2004-06-30 Abbot Gmbh & Co Kg Pirazolopirimidinas como agentes terapeuticos.
US7402312B2 (en) 2001-04-13 2008-07-22 Human Genome Sciences, Inc. Antibodies to vascular endothelial growth factor 2 (VEGF-2)
JP2004536579A (ja) 2001-04-13 2004-12-09 ヒューマン　ジノーム　サイエンシーズ，　インコーポレイテッド 血管内皮増殖因子２
AU2002345603B2 (en) * 2001-06-07 2006-10-12 Skinmedica, Inc. Conditioned cell culture media and uses thereof
AU2002322461B2 (en) * 2001-07-12 2007-12-06 Vegenics Limited Lymphatic endothelial cells materials and methods
US7514261B2 (en) * 2001-08-09 2009-04-07 Cornell Research Foundation, Inc. Platelet-derived growth factor protection of cardiac myocardium
US20030113324A1 (en) * 2001-10-01 2003-06-19 Kari Alitalo Neuropilin/VEGF-C/VEGFR-3 materials and methods
US20040214766A1 (en) * 2001-10-01 2004-10-28 Kari Alitalo VEGF-C or VEGF-D materials and methods for treatment of neuropathologies
BR0213325A (pt) 2001-10-15 2004-10-13 Janssen Pharmaceutica Nv Derivados de 4-fenil-4-[1h-imidazol-2-il]-piperidina substituìda para a redução de dano isquêmico
EP2277910A1 (de) 2001-12-21 2011-01-26 Human Genome Sciences, Inc. Albumin Fusionsproteine
JP2005536186A (ja) * 2002-03-07 2005-12-02 ルードビッヒ、インスティテュート、フォー、キャンサー、リサーチ リンパ管および血管内皮細胞遺伝子
US7510714B2 (en) * 2002-04-01 2009-03-31 Trustees Of Dartmouth College Methods for modulating angiogenesis
US7241446B2 (en) * 2002-04-01 2007-07-10 Trustees Of Dartmouth College Methods for modulating angiogenesis via VEGF
US20030228283A1 (en) * 2002-05-03 2003-12-11 Ludwig Institute For Cancer Research Preventing secondary lymphedema with VEGF-D DNA
CN100418981C (zh) 2002-06-10 2008-09-17 瓦西尼斯公司 在乳腺癌和膀胱癌中差异表达的基因及编码多肽
CA2493572A1 (en) 2002-07-23 2004-01-29 Ludwig Institute For Cancer Research Methods and compositions for activating or inhibiting vegf-d and vegf-c
US20040120950A1 (en) * 2002-12-20 2004-06-24 Kari Alitalo Modulation of VEGF-C/VEGFR-3 interactions in the treatment of rheumatoid arthritis
US20040248796A1 (en) * 2003-02-04 2004-12-09 Kari Alitalo VEGF-B and PDGF modulation of stem cells
WO2005016963A2 (en) * 2003-06-12 2005-02-24 Ludwig Institute For Cancer Research Heparin binding veger-3 ligands
US20050043235A1 (en) * 2003-06-12 2005-02-24 Kari Alitalo Use of VEGF-C or VEGF-D in reconstructive surgery
US20070110744A1 (en) * 2003-09-08 2007-05-17 Kari Alitalo Lymphatic and blood endothelial cell genes
US7284505B1 (en) 2003-11-03 2007-10-23 Paxton Stephen E Skijor system
US7780973B2 (en) * 2003-12-15 2010-08-24 Ethicon Endo-Surgery, Inc. Method and device for minimally invasive implantation of biomaterial
WO2005063807A2 (en) * 2003-12-29 2005-07-14 Centelion Treatment of coronary or peripheral ischemia
US20050142161A1 (en) * 2003-12-30 2005-06-30 Freeman Lynetta J. Collagen matrix for soft tissue augmentation
WO2005087812A1 (en) * 2004-03-05 2005-09-22 Ludwig Institute For Cancer Research Multivalent antibody materials and methods for vegf/pdgf family of growth factors
US20060024302A1 (en) * 2004-03-05 2006-02-02 Ludwig Institute For Cancer Research Chimeric anti-VEGF-D antibodies and humanized anti-VEGF-D antibodies and methods of using same
WO2005093098A1 (en) * 2004-03-12 2005-10-06 Ludwig Institute For Cancer Research Differential drug sensitivity
US7595149B1 (en) 2004-11-08 2009-09-29 University Of Kentucky Research Foundation Methods for cancer detection
EP2314614B1 (de) 2005-02-28 2015-11-25 Sangamo BioSciences, Inc. Anti-angiogene Verfahren und Zusammensetzungen
EP1919944B1 (de) 2005-08-15 2011-03-23 Vegenics Pty Ltd Modifizierte vegf und pdgf mit verbesserten angiogenen eigenschaften
TW200732347A (en) * 2005-10-06 2007-09-01 Trophogen Inc VEGF analogs and methods of use
ES2350269T3 (es) * 2006-01-18 2011-01-20 The General Hospital Corporation Métodos de aumento de la función linfática.
ES2497641T3 (es) 2006-05-17 2014-09-23 The Ludwig Institute For Cancer Research Dirección a la regulación de VEGF-B de transportadores de ácidos grasos para modular enfermedades humanas
US9073997B2 (en) 2007-02-02 2015-07-07 Vegenics Pty Limited Growth factor antagonists for organ transplant alloimmunity and arteriosclerosis
WO2008096268A2 (en) * 2007-02-07 2008-08-14 Vegenics Limited Autologous lymph node transfer in combination with vegf-c or vegf-d growth factor therapy to treat secondary lymphedema and to improve reconstructive surgery
US7811776B2 (en) 2007-12-05 2010-10-12 University Of Cincinnati Use of VEGF-D in the diagnosis of lymphangioleiomyomatosis (LAM) disease
AU2008341050B2 (en) 2007-12-26 2013-10-24 Vaccinex, Inc. Anti-C35 antibody combination therapies and methods
WO2009143584A1 (en) * 2008-05-30 2009-12-03 Vegenics Limited Treatment of pulmonary edema
US20100029491A1 (en) * 2008-07-11 2010-02-04 Maike Schmidt Methods and compositions for diagnostic use for tumor treatment
US8255807B2 (en) * 2008-12-23 2012-08-28 Ganz Item customization and website customization
AU2010230855A1 (en) * 2009-04-03 2012-01-12 Vegenics Limited Anti-VEGF-D antibodies
WO2011056494A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
WO2011106697A1 (en) * 2010-02-25 2011-09-01 Schepens Eye Research Institute Therapeutic compositions for the treatment of dry eye disease
WO2011154308A1 (en) 2010-06-08 2011-12-15 Proyecto De Biomedicina Cima, S.L. New compositions and cell therapy methods for the treatment of cirrhosis
WO2012088563A1 (en) * 2010-11-24 2012-07-05 Vegenics Pty Limited Vegfr-2-specific forms of vegf-d and vegf-c and uses thereof
WO2012154983A2 (en) 2011-05-10 2012-11-15 Biocare Medical, Llc Systems and methods for anti-pax8 antibodies
US9415090B2 (en) * 2011-06-01 2016-08-16 Universität Heidelberg VEGF-D/VEGFR2/3-mediated regulation of dendrites
US10316103B1 (en) 2012-03-30 2019-06-11 Biocare Medical, Llc Systems and methods for anti-Uroplakin III antibodies
CA3108181A1 (en) 2012-07-30 2014-02-06 Trophogen Inc. Glycoprotein hormone long-acting superagonists
US10457713B2 (en) 2012-07-30 2019-10-29 Trophogen, Inc. Glycoprotein hormone long-acting superagonists
EP2900265B1 (de) 2012-09-27 2018-05-30 Biocare Medical, LLC Anti-uroplakin-ii-antikörper, systeme und verfahren
US10429390B2 (en) 2012-12-18 2019-10-01 Biocare Medical, Llc Antibody cocktail systems and methods for classification of histologic subtypes in lung cancer
RS60026B1 (sr) 2013-02-18 2020-04-30 Vegenics Pty Ltd Molekuli koji vezuju ligande i njihove upotrebe
EP2962113B1 (de) 2013-02-28 2019-04-03 Biocare Medical, LLC Systeme und verfahren mit anti-pd40-antikörpern
EP3052522B1 (de) 2013-10-03 2019-12-11 Biocare Medical, LLC Anti-sox10-antikörpersysteme und verfahren
JP2017502079A (ja) 2013-11-05 2017-01-19 トロフォジェン インコーポレイテッド 糖タンパク質ホルモン長時間作用性スーパーアゴニスト
EP3924367A4 (de) * 2019-04-04 2022-10-12 Sree Chitra Tirunal Institute for Medical Sciences and Technology Gefässendothelwachstumsfaktor (vegf) zur besseren wundheilung durch erhöhte angiogenese
US20240150807A1 (en) * 2021-03-10 2024-05-09 Sumitomo Pharma Co., Ltd. Method for Producing Cysteine Knot Protein

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968778A (en) 1989-01-12 1999-10-19 Jurgen Hoppe PDGF-AB, preparation process and pharmaceuticals containing them
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US6207454B1 (en) * 1989-10-16 2001-03-27 Amgen Inc. Method for enhancing the effciency of gene transfer with stem cell factor (SCF) polypeptide
US5476839A (en) * 1990-07-10 1995-12-19 Incyte Pharmaceuticals, Inc. Basophil granule proteins
JP3024311B2 (ja) 1991-10-03 2000-03-21 味の素株式会社 Ｉｌ−２受容体重鎖に結合するポリペプチド
JPH05271294A (ja) 1992-01-24 1993-10-19 Japan Found Cancer Res ヒトプロヒビチンおよびそれをコードするｄｎａ
PL307258A1 (en) 1992-07-27 1995-05-15 Pfizer Peptides capable to block calcium canals with agelenopsis aperta
US5510239A (en) * 1993-10-18 1996-04-23 Isis Pharmaceuticals, Inc. Oligonucleotide modulation of multidrug resistance-associated protein
AU696764B2 (en) 1994-03-08 1998-09-17 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
DE4423098A1 (de) 1994-07-01 1996-01-04 Hoechst Ag Verwendung von Pyrimidingruppen enthaltenden konjugierten Verbindungen als Elektrolumineszenzmaterialien
US5814464A (en) 1994-10-07 1998-09-29 Regeneron Pharma Nucleic acids encoding TIE-2 ligand-2
US6645933B1 (en) * 1995-08-01 2003-11-11 Helsinki University Licensing Ltd. Oy Receptor ligand VEGF-C
US6221839B1 (en) * 1994-11-14 2001-04-24 Helsinki University Licensing Ltd. Oy FIt4 ligand and methods of use
JPH08185216A (ja) 1994-12-28 1996-07-16 Meidensha Corp 工具姿勢パラメータ設定方法及びロボット制御装置
US5928939A (en) 1995-03-01 1999-07-27 Ludwig Institute For Cancer Research Vascular endothelial growth factor-b and dna coding therefor
CN1194090C (zh) 1995-03-02 2005-03-23 阿穆拉德业务有限公司 一种新的生长因子和编码这种生长因子的基因序列
WO1996039421A1 (en) 1995-06-06 1996-12-12 Human Genome Sciences, Inc. Human vascular endothelial growth factor 3
EP0848755B2 (de) * 1995-09-08 2011-02-09 Genentech, Inc. Vegf-verwandtes protein
AU7142996A (en) * 1995-09-29 1997-04-28 Universita' Degli Studi Di Siena Regulated genes and uses thereof
JP3843488B2 (ja) 1996-06-06 2006-11-08 アイシン・エィ・ダブリュ株式会社 自動変速機の制御装置
EP0935001B2 (de) 1996-07-15 2011-08-10 Chugai Seiyaku Kabushiki Kaisha Neuartige vegf-ähnliche faktoren
EP0956339B1 (de) 1996-08-23 2005-10-12 Ludwig Institute For Cancer Research Rekombinanter vaskulärer endothelzellen wachstumsfaktor d (vegf-d)
AU5439998A (en) 1996-12-06 1998-06-29 Zymogenetics Inc. Vascular endothelial growth factor
US20020165174A1 (en) * 1997-01-31 2002-11-07 Gill Parkash S. Methods and compositions for antisense VEGF oligonucleotides
EP1054687B8 (de) 1997-12-24 2008-07-16 Vegenics Limited Expressionsvektoren und zellinien zur expression von vaskulärem wachstumsfaktor d, sowie verfahren zur behandlung von melanomen
DE19817835C2 (de) 1998-04-22 2000-05-18 Billhofer Maschf Gmbh Sichtkaschiervorrichtung
DE19823359C1 (de) 1998-05-15 1999-10-07 Francotyp Postalia Gmbh Vorrichtung zum Bedrucken von Postgut
DK1140175T3 (da) 1998-12-21 2006-08-14 Ludwig Inst Cancer Res Antistoffer mod trunkeret VEGF-D og anvendelser deraf
CA2381985A1 (en) * 1999-08-16 2001-02-22 Universita'degli Studi Di Siena Vegf-d and angiogenic use thereof
US20050043235A1 (en) 2003-06-12 2005-02-24 Kari Alitalo Use of VEGF-C or VEGF-D in reconstructive surgery
US20070212390A1 (en) 2005-09-22 2007-09-13 Ludwig Institute For Cancer Research Protease-resistant forms of VEGF-D, method of making and method of use
FR2987282B1 (fr) 2012-02-24 2017-12-29 Fonds De L'espci Georges Charpak Microcanal avec dispositif d'ouverture et/ou fermeture et/ou pompage
US9405291B2 (en) 2012-07-31 2016-08-02 Fisher-Rosemount Systems, Inc. Systems and methods to monitor an asset in an operating process unit
US9516755B2 (en) 2012-12-28 2016-12-06 Intel Corporation Multi-channel memory module
US9426605B2 (en) 2013-10-10 2016-08-23 Yahoo! Inc. Cross device information exchange using gestures and locations

Also Published As

Publication number Publication date
US7871798B2 (en) 2011-01-18
US7785803B2 (en) 2010-08-31
ES2251740T3 (es) 2006-05-01
CA2263890C (en) 2013-05-14
US20060177428A1 (en) 2006-08-10
DK1749836T3 (da) 2009-08-31
US7662932B2 (en) 2010-02-16
US20040175730A1 (en) 2004-09-09
US20030125537A1 (en) 2003-07-03
US7122654B2 (en) 2006-10-17
EP1283268A2 (de) 2003-02-12
EP1749836A3 (de) 2007-08-22
DK0956339T3 (da) 2006-01-30
AU729880C (en) 2001-11-08
US6235713B1 (en) 2001-05-22
EP2107109B1 (de) 2012-06-20
US20110281799A1 (en) 2011-11-17
HK1025789A1 (en) 2000-11-24
EP1749836A2 (de) 2007-02-07
US20120322105A1 (en) 2012-12-20
EP0956339A4 (de) 2000-08-23
US7410639B2 (en) 2008-08-12
ES2327440T3 (es) 2009-10-29
WO1998007832A1 (en) 1998-02-26
DE69734359T2 (de) 2006-07-06
EP0956339B1 (de) 2005-10-12
US8445234B2 (en) 2013-05-21
ATE434034T1 (de) 2009-07-15
US20030114658A1 (en) 2003-06-19
JP2001517075A (ja) 2001-10-02
US20080070831A1 (en) 2008-03-20
EP2107109A1 (de) 2009-10-07
DK2107109T3 (da) 2012-09-24
DE69734359D1 (de) 2006-02-23
US7928061B2 (en) 2011-04-19
AU4079697A (en) 1998-03-06
US8759286B2 (en) 2014-06-24
EP1749836B1 (de) 2009-06-17
US20090087905A1 (en) 2009-04-02
EP0956339A1 (de) 1999-11-17
US6689580B1 (en) 2004-02-10
US8227410B2 (en) 2012-07-24
US20130345409A1 (en) 2013-12-26
ES2390107T3 (es) 2012-11-06
US20080145366A1 (en) 2008-06-19
CA2263890A1 (en) 1998-02-26
JP2009291198A (ja) 2009-12-17
US20080058258A1 (en) 2008-03-06
US20070298493A1 (en) 2007-12-27
JP2007167072A (ja) 2007-07-05
EP1283268A3 (de) 2004-01-02
DE69739469D1 (de) 2009-07-30
AU729880B2 (en) 2001-02-15

Similar Documents

Publication Publication Date Title
DK0956339T3 (da) Rekombinant vaskulær endotelcellevækstfaktor D (VEGF-D)
NO973933L (no) Vaskulær endotelvekstfaktor B
DE69941791D1 (de) Von blutplättchen abstammender wachstumsfaktor d, dafür kodierende dns und deren verwendungen
DE3851153D1 (de) Genetische modifizierung von endothelialen zellen.
PT93910A (pt) Prodesso para a preparacao de uma proteina heterologa mediante secrecao a partir de uma celula
DE69839340D1 (de) Mutanten DES VASKULÄREN, ENDOTHELZELLEN-SPEZIFISCHEN WACHSTUMSFAKTORS C (VEGF-C) UND DEREN VERWENDUNGEN
ATE309360T1 (de) Vaskularer endothelialer wachstumsfaktor 2
DE3786321D1 (de) Expression von protein-c.
DK0409472T3 (da) Knoglemorfogenetisk protein
DE69434332D1 (de) Thrombin mutanten
IL70776A (en) Recombinant dna molecule encoding at least one polypeptide displaying the immunogenicity of at least one merozoite antigen or asexual blood stage antigen of p.falciparum,vectors comprising the dna molecule,host cells transformed thereby,immunogenic polypeptides produced by host cells and compositions containing the polypeptides
ATE121776T1 (de) Expression des biologisch aktiven faktors xiii.
WO2002050111A3 (en) Isolated laminin 10
WO2001053324A8 (en) Novel haptotactic peptides
WO1990003394A3 (fr) Nouvelles lymphokines, sequences d'adn codant pour ces lymphokines et compositions pharmaceutiques contenant ces lymphokines
WO2002059618A3 (en) Growth factor polypeptides and nucleic acids encoding same

Legal Events

Date Code Title Description
EEIH Change in the person of patent owner
UEP Publication of translation of european patent specification

Ref document number: 0956339

Country of ref document: EP

REN Ceased due to non-payment of the annual fee